Evaxion Biotech A/S (NASDAQ:EVAX) Short Interest Update

Evaxion Biotech A/S (NASDAQ:EVAX) saw a large drop in short interest in the month of February. As of February 15th, there was short interest totalling 58,600 shares, a drop of 52.9% from the January 31st total of 124,500 shares. Approximately 5.5% of the company’s stock are sold short. Based on an average trading volume of 2,240,000 shares, the short-interest ratio is currently 0.0 days.

Evaxion Biotech A/S Stock Down 7.6 %

NASDAQ:EVAX traded down $0.16 on Friday, reaching $1.94. 165,833 shares of the stock traded hands, compared to its average volume of 3,639,702. The company has a market capitalization of $2.28 million, a price-to-earnings ratio of -1.34 and a beta of -0.28. The company has a current ratio of 1.00, a quick ratio of 2.80 and a debt-to-equity ratio of 7.99. Evaxion Biotech A/S has a 12 month low of $1.89 and a 12 month high of $22.05. The company’s fifty day simple moving average is $3.40 and its 200 day simple moving average is $9.20.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on EVAX shares. Lake Street Capital lowered their price target on shares of Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, February 4th. HC Wainwright reissued a “buy” rating and set a $14.00 price target on shares of Evaxion Biotech A/S in a research report on Thursday, February 20th.

Institutional Investors Weigh In On Evaxion Biotech A/S

An institutional investor recently bought a new position in Evaxion Biotech A/S stock. Catalina Capital Group LLC acquired a new stake in shares of Evaxion Biotech A/S (NASDAQ:EVAX) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned about 2.98% of Evaxion Biotech A/S as of its most recent SEC filing. 11.04% of the stock is owned by institutional investors.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.